Systemic sclerosis (SSc) is an idiopathic disorder of connective tissue characterized by vascular damage, inflammation, and tissue fibrosis. 1 Cutaneous fibrosis is the most characteristic feature of SSc, resulting from excessive deposition of extracellular matrix proteins by activated dermal fibroblasts. 2 This activation results from immune mediators and growth factors produced by inflammatory cells in the skin of patients with SSc, ultimately leading to excessive fibrosis. 3 In previous work we have shown that severe skin thickening in patients with SSc is linked to IL-13 overproduction by CD8 1 T cells, 4, 5 inducing a profibrotic phenotype in fibroblasts from healthy donors and patients with SSc. 5, 6 In comparison, CD4
1
T cells from patients produce lower and more variable levels of IL-13. 4 Furthermore, we observed high numbers of CD8 1 IL-13 1 cells in the fibrotic skin of patients with SSc, especially in early stages of disease. 5, 6 In parallel, we established that blood CD8 1 T cells from patients with SSc express a high level of the transcription factor GATA-3, which correlates with levels of IL-13 production and the extent of cutaneous fibrosis. 7 Moreover, small interfering RNA (siRNA) silencing of GATA-3 blocks IL-13 production in CD8 1 T cells from patients with SSc, 7 demonstrating a causal relationship between GATA-3 and IL-13.
GATA-3 is the master regulator of T H 2 cell differentiation and regulates expression of the type 2 signature cytokines IL-4, IL-5, and IL-13. 8, 9 GATA-3 is also involved in the development, maintenance, and effector function of other CD4
1 and CD8 1 T-cell subsets, as well as in the generation of invariant natural killer T cells and type 2 innate lymphoid cells. 10 Expression of GATA-3 is regulated by multiple factors, 8, 9 including the transcription factor T-bet, a key player in the commitment of T H cells to the T H 1 lineage. 11 T-bet induces IFN-g transcription [11] [12] [13] and simultaneously inhibits the production of T H 2 cytokines, including IL-13, 11 by antagonizing GATA-3 expression, function, or both. 14, 15 During T H 1 differentiation, the IL-2-inducible T-cell kinase (ITK) phosphorylates T-bet at Tyr525. 16 Although this modification does not affect the ability of T-bet to induce IFN-g, it facilitates the association of T-bet with GATA-3 and prevents the binding of GATA-3 to the IL-4/IL-5/IL-13 cytokine locus, resulting in suppression of type 2 cytokine production. 16 Previously, we found that skin and blood CD8
1 T cells from patients with SSc coexpress high levels of IL-13 and IFN-g, 4 ,5 suggesting that T-bet is unable to modulate GATA-3 function. 7 The aim of this study was to determine the molecular basis underlying IL-13 upregulation by CD8
1 T cells from patients with SSc. We established that the interaction of T-bet with the adaptor protein 14-3-3z in the cytosol of CD8
1 T cells from patients with SSc restricts T-bet translocation into the nucleus and its ability to associate with GATA-3. Consequently, more GATA-3 bound to the IL-13 promoter and induced IL-13 expression. Interestingly, this mechanism was not found in CD8
1 T cells from healthy control subjects or patients with rheumatoid arthritis (RA) but was used during type 2 priming of CD8 1 T cells from healthy donors. Thus our data identify a novel molecular mechanism underlying type 2 cytokine production by CD8 1 T cells and have revealed a more complete picture of the complex pathway leading to IL-13 overexpression in SSc pathogenesis.
METHODS

Blood and skin samples
Seventy-six patients were recruited from the Scleroderma Clinic of the University of Pittsburgh Medical Center who fulfilled either the classification criteria for SSc proposed by the American College of Rheumatology 17 or the diagnostic criteria of LeRoy et al. 18 Disease subtype and internal organ involvement were assessed according to established criteria. 19, 20 Based on previous studies, 4, 6 we selected patients with diffuse cutaneous systemic sclerosis (dcSSc) who were in an early active disease stage (duration <3 years). 21 These patients have rapidly progressive widespread fibrosis of the skin and early fibrosis of the lungs and other internal organs. 18 Patients were 29 to 73 years old (mean 6 SD, 47.5 6 12.7 years), and the female/male ratio was 4:1. We obtained 54 blood samples and 22 full-thickness skin biopsy specimens (3 mm). At the time samples were collected, patients were not treated with any immunosuppressive medications or were treated with low-dose prednisone (5-10 mg/d).
Control blood (n 5 48) and skin (n 5 5) samples were obtained from age-and sex-matched healthy donors with no history of any connective tissue disease recruited at the University of Pittsburgh Medical Center Arthritis and Autoimmunity Center. Age range was 28 to 68 years, and the female/male ratio was 3:4.
Research protocols involving human subjects were approved by the Institutional Review Board of the University of Pittsburgh. All participants provided written informed consent in accordance with the Declaration of Helsinki.
Cell isolation and culture
CD8
1 T cells were isolated from blood, as previously reported. 4 Naive CD8 1 T cells were obtained by using the Na€ ıve CD8 1 T Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). 7 The purity of each T-cell subpopulation was greater than 90%, as determined by using flow cytometry. Cells were isolated from skin by using the Whole Dissociation Skin Kit (Miltenyi Biotec). 5 When indicated, cells were activated in vitro for 5 days (T H 0/T C 0) or primed under type 1 (T H 1/T C 1) or type 2 (T H 2/T C 2) culture conditions, as previously described. 7 Quantitative RT-PCR Quantitative reverse RT-PCR (qPCR) analysis was performed, as previously described. 7 Human glyceraldehyde-3-phosphate dehydrogenase was used as an endogenous control to normalize gene expression data. All reagents and primers were purchased from Applied Biosystems (Foster City, Calif). The SDS 2.1 software (Applied Biosystems) was used for data analysis.
Western blotting and immunoprecipitation
Standard methods for immunoblot analysis were used. 22 Additional details are reported in Fig E1 in this article' s Online Repository at www.jacionline.org.
Flow cytometry and Amnis ImageStream
GATA-3, T-bet, and IL-13 protein expression was determined by means of intracellular staining, as previously described. 4, 7 Labeled cells were analyzed on an LSRII flow cytometer (Becton Dickinson, San Jose, Calif) by using FlowJo software (TreeStar, Ashland, Ore).
For imaging flow cytometry, samples were acquired with the ImageStream MKII cytometer (Amnis-EMD Millipore, Burlington, Mass), and data were analyzed with IDEAS software (Amnis).
Immunohistochemistry and immunofluorescence microscopy
Immunohistochemistry was performed, as described previously. 6 Images were obtained with an Evos FL Auto microscope (Life Technologies, Grand Island, NY). Results are expressed as a percentage of positive cells out of the entire infiltrate after quantification of 20 high-power fields (3400 magnification).
Immunofluorescence staining on frozen skin samples and blood CD8
1 lymphocytes was performed, as previously reported. 23 Confocal images were captured on an Olympus Fluoview 1000 confocal microscope (Olympus, Center Valley, Pa) by using an oil immersion 360 objective.
Chromatin immunoprecipitation
Cells were subjected to chromatin immunoprecipitation (ChIP) based on the ChIP-IT High Sensitivity Kit protocol (Active Motif). Chromatin was immunoprecipitated with rabbit anti-GATA-3 mAb or normal rabbit immunoglobulin G (Santa Cruz Biotechnology, Dallas, Tex). qPCR analysis was performed to determine the relative abundance of target DNA. DNA immunoprecipitated by GATA-3 antibody was normalized to total DNA input.
siRNA transfection
Freshly isolated CD8
1 T cells were transfected with 4 mmol/L ITK or 14-3-3z ON-TARGETplus SMARTpool siRNA or the ON-TARGETplus Non Targeting siRNA #1 (negative control; Thermo Scientific, Dharmacon, Lafayette, Colo) by using the Amaxa Human T Cell Nucleofector Kit (Lonza, Basel, Switzerland), as previously described. 7 ITK or 14-3-3z depletion was determined 48 hours after nucleofection by using Western blotting.
Statistical analysis
We used the unpaired Student t test or 1-way ANOVA, followed by the post hoc Tukey-Kramer test (InStat software; GraphPad Software, La Jolla, Calif). We considered a P value of less than .05 as significant, a P value of less than .01 as very significant, and a P value of less than .001 as highly significant. A, Representative hematoxylin and eosin (H&E) staining (upper panel) and GATA-3 immunohistochemical staining (lower panel) of skin biopsy specimens of normal skin (NS) (n 5 5), patients with early dcSSc (n 5 5), or patients with late dcSSc (n 5 5), each at 3200 and 3400 magnification. Fig 1, A, right panel, Quantification of the GATA-3 1 cellular infiltrate in tissue sections by using microscopy is expressed as mean 6 SD measurements from 20 high-power fields. Statistics were determined by using ANOVA, followed by the Tukey post hoc test. *P < .05 and ***P < .001. B, Representative examples of double color immunofluorescence staining for CD8 (surface staining) and GATA-3 (nuclear staining) at 3400 and 31000 magnification. Skin samples from 5 patients with early dcSSc were analyzed, producing similar results. 49-6-Diamidino-2-phenylindole dihydrochloride (DAPI) stains nuclei.
RESULTS
CD8
1 T cells from blood and lesional skin of patients with dcSSc upregulate GATA-3 expression and coexpress high levels of T-bet
Using immunohistochemical analysis, we show that high numbers of GATA-3
1 cells are present in the sclerotic skin of patients (Fig 1) . The number of GATA-3 1 inflammatory cells is greater in the skin of patients in the early active inflammatory stage of the disease, whereas lower numbers are found in the skin of patients with late-stage disease (Fig 1, A, right panel) . GATA-3 1 inflammatory infiltrates localized in the lower dermis and subdermal fat, whereas normal skin was negative for these cells. In addition to inflammatory cells, other cell types, such as endothelial cells and fibroblasts, express GATA-3 in the skin of patients with SSc but not in normal skin (see Table E1 in this article's Online Repository at www.jacionline.org). Using doublecolor immunofluorescence microscopy, we found numerous CD8 
GATA-3
1 cells in the affected skin of patients with early active dcSSc (Fig 1, B) .
To elucidate the molecular processes associated with GATA-3 upregulation by CD8
1 T cells from patients with SSc, we analyzed T-bet modulation of GATA-3 activity. We first assessed T-bet and GATA-3 levels in in vitro-activated naive CD8
1 T cells purified from the peripheral blood of patients with dcSSc and agematched normal donors (NDs). mRNA levels of T-bet and GATA-3 were determined by using qPCR (Fig 2, A) , and protein levels were determined by using Western blotting (Fig 2, B) . In all experiments we found that although GATA-3 levels were increased in CD8 1 T cells from patients compared with those from control subjects, T-bet levels were comparable. Interestingly, using flow cytometry, we observed a statistically significant increase in the frequency of CD8 patients' samples compared with CD8 1 T cells from NDs (P < .01; Fig 2, C) .
We next determined GATA-3 and T-bet expression by CD8 1 T cells isolated from the affected skin of patients with early dcSSc. Cell suspensions were prepared from 3-mm skin biopsy specimens and analyzed by using multicolor flow cytometry, as previously described. 5 We identified CD8 1 T cells from patients' skin samples (Fig 2, D) . However, as in previous studies, 5 we could not obtain sufficient CD8 1 T cells from normal skin for analysis (patients with SSc, 3.1% 6 0.8%; NDs, 0.7% 6 0.8%). The majority of CD8 1 T cells in the skin of patients coexpressed GATA-3 and T-bet both in freshly isolated CD8 1 T cells (72.3% 6 Primers to the human IL-13 gene promoter were used for qPCR (see the Methods section). Error bars represent means 6 SDs from 7 determinations. Statistics were determined by using ANOVA, followed by the Tukey post hoc test. IP, Immunoprecipitation; WB, Western blotting. **P < . 01 and ***P < .001.
and skin indicated that the proportion of double-positive cells was highly increased in the affected skin compared with blood (64.3% 6 13.8% vs 12.5% 6 4.1%, respectively; P < .001).
Remarkably, these frequencies parallel those of CD8 1
IL-13
1 IFN-g 1 T cells found in the skin and blood of patients, respectively. 5 Association between T-bet and GATA-3 levels is reduced in CD8
1 lymphocytes from patients with SSc and human T C 2 cells, allowing more GATA-3 binding to the IL-13 promoter
We purified naive CD4 1 and CD8 1 T cells from NDs and primed them in vitro in type 1 and type 2 culture conditions. After 5 days in culture, we prepared cell lysates from each cell culture to detect T-bet/GATA-3 complexes by means of immunoprecipitation with anti-T-bet mAb followed by immunoblotting with anti-GATA-3 mAb (Fig 3, A) . As observed in mouse CD4
1 T cells, 16 we found that the association between T-bet and GATA-3 was more pronounced in human T cells primed under type 1 culture conditions and decreased in T H 2 and T C 2 cells (Fig 3, A, lower panel) . As expected, T H 1 and T C 1 cells are characterized by low GATA-3/T-bet ratios and produced high levels of IFN-g but no IL-13, whereas T H 2 and T C 2 cells exhibited high GATA-3/T-bet ratios and produced high levels of IL-13 and no IFN-g (Fig 3, B , and see tients with SSc and NDs by using the SS. 25 ,26 D, T-bet and GATA-3 levels determined by using Western blotting in nuclear and cytosolic proteins isolated from CD8 1 T cells from NDs (n 5 8) and patients with SSc (n 5 11). Actin and histone H4 were used as loading controls. A representative example is shown in the left panel, and the nuclear/cytosolic ratio of all samples tested is shown in the right panel. Statistics were performed by using the Student t test. E, Confocal immunofluorescence microscopy of CD8 1 T cells fixed and stained with anti-T-bet (red). Nuclei were stained with DAPI (3600 magnification). F, Nuclear proteins were isolated from CD8 1 T cells of samples from NDs (n 5 5) and patients with SSc (n 5 8) and immunoprecipitated with anti-T-bet or control IgG antibodies. Immunoprecipitated proteins were immunoblotted with anti-GATA-3 and anti-T-bet antibodies (middle and lower panels). T-bet expression was evaluated by means of Western blotting, and H4 was used as a loading control (upper panel). Densitometric analysis of band intensity was performed with ImageJ software (right panel), as described in Fig 3, B. IP, Immunoprecipitation; WB, Western blotting. ***P < .001.
We next compared the interaction between T-bet and GATA-3 levels in CD8
1 T cells isolated from a well-characterized cohort of patients with early active dcSSc and age-matched NDs (Fig 3,  C) . We found that in most of the patients analyzed, the intensity of the T-bet/GATA-3 association was decreased compared with that in NDs (Fig 3, C) . This was observed in freshly isolated CD8 1 T cells but more pronounced in naive cells stimulated in vitro for 5 days (Fig 3, C) . Similar results were obtained in activated total CD8
1 T cells (data not shown). In comparison, we detected a modest but comparable association between T-bet and GATA-3 levels in CD4
1 T cells from patients with SSc and control subjects, which is in agreement with our previous observations showing that type 2 cytokine production is more a feature of CD8 rather than CD4 T cells in patients with SSc (see Fig E2,  C and D) . 4, 24 Of note, we observed that the interaction between T-bet and GATA-3 in CD8
1 T cells from patients with RA was similar to that in NDs (see Fig E1 in this article' s Online Repository at www.jacionline.org).
We performed ChIP analysis to determine whether the diminished interaction between T-bet and GATA-3 in CD8
1 T cells from patients with SSc affected GATA-3 binding to the IL-13 promoter. We established that more GATA-3 bound to the IL-13 promoter of CD8 1 T cells from patients with SSc compared with CD8
1 lymphocytes from NDs but similarly to T C 2 and T H 2 cells from NDs (Fig 3, D) .
Decreased nuclear T-bet levels correlate with a lower T-bet/GATA-3 association in CD8
1 T cells in patients with dcSSc
In vitro-activated CD8
1 T cells stained for T-bet and GATA-3 were analyzed with the ImageStream flow cytometer to visualize T-bet/GATA-3 colocalization in CD8
1 T cells from patients with SSc and NDs on a single-cell level. ImageStream technology combines flow cytometry with cell imaging to provide spatial and intensity information within individual cells. 25, 26 IDEAS software was used to calculate T-bet/GATA-3 colocalization by using a similarity score (SS) of greater than 1, which corresponds to high correlations between T-bet and GATA-3 pixel values per cell. 25, 26 Representative images of the gating strategy, histograms of SSs between an ND and a patient with early dcSSc, and cell images from individual bins are shown in Fig 4, A- (Fig 4, D) . The nuclear/cytoplasmic ratios of T-bet and GATA-3 levels measured in multiple samples indicated that although the GATA-3 ratios are comparable in CD8 1 T cells from patients and control subjects, those for T-bet are greatly diminished in CD8 1 T cells from patients with SSc (Fig 4, D) .
T-bet subcellular localization was also evaluated by using confocal microscopy. In accord with our imaging flow and cell fractionation data, we found that T-bet was almost exclusively localized in the nuclei of CD8 1 T cells from NDs, whereas in CD8 1 T cells from patients with SSc, T-bet was detected in both nuclei and cytosol (Fig 4, E) . Finally, immunoprecipitation analysis of nuclear extracts from CD8 1 cells from patients with SSc and NDs confirmed a weaker nuclear interaction between T-bet and GATA-3 in patients' CD8
1 lymphocytes compared with cells from NDs (Fig 4, F) .
Tyrosine phosphorylation of T-bet by ITK does not affect T-bet subcellular distribution
Tyrosine phosphorylation of T-bet protein modulates lineage commitment during T-cell differentiation. 16 ,27,28 Thus we determined the levels of tyrosine-phosphorylated T-bet in purified naive CD8
1 T cells from patients with SSc and NDs after in vitro activation. Nuclear lysates obtained from cell cultures were immunoprecipitated with anti-T-bet antibody, followed by immunoblotting with anti-phospho-tyrosine (4G10). Levels of tyrosine-phosphorylated T-bet were found to be higher in the nuclei of CD8 1 T cells from NDs compared with samples from patients with SSc (Fig 5, A) . Multiple tyrosine phosphorylation sites have been identified on T-bet 16, 27 ; however, T-bet phosphorylation at Tyr525 by ITK was shown to mediate the interaction between T-bet and GATA-3. 16 We established that similar levels of ITK are present in CD8 1 T cells from NDs and patients with SSc (Fig 5, B) .
To determine whether ITK-dependent tyrosine phosphorylation of T-bet affected its translocation from the cytosol to the nucleus, we determined T-bet subcellular distribution in CD8 1 cells from NDs after ITK silencing (Fig 5, C) . This analysis revealed that levels of T-bet in the nucleus and cytosol were unchanged after ITK siRNA silencing. Conversely, immunoprecipitation experiments with an anti-T-bet antibody followed by immunoblotting with phosphotyrosine or GATA-3 antibodies showed that levels of tyrosine-phosphorylated T-bet and T-bet/GATA-3 association are both diminished after ITK siRNA (Fig 5, D) .
The adaptor protein 14-3-3z binds to T-bet in T C 2 cells and CD8 1 T cells from patients with SSc and prevents its translocation to the nucleus
We performed mass spectrometric screening for T-bet-immunoprecipitated proteins from CD8 1 T cells from patients and control subjects to identify potential factors that bind specifically to T-bet in CD8
1 lymphocytes from patients with SSc and that might act to prevent its translocation into the nucleus. This analysis suggested that the adaptor protein 14-3-3z, which is involved in regulating subcellular localization of many transcription factors, 29 interacts specifically with T-bet in CD8 1 T cells from patients but not from control subjects (see Fig E3, B) .
To confirm this finding, we performed 14-3-3z immunoblot analysis of T-bet-immunoprecipitated proteins from CD8 1 cells from multiple patients and NDs (Fig 6, A) . Strikingly, we found that 14-3-3z associated with T-bet uniquely in CD8
1 lymphocytes from patients with SSc but not in CD8 1 cells from NDs or patients with RA both in freshly isolated and in vitro-activated naive CD8 1 T cells (Fig 6, A , and see Fig E1, A) . Importantly, we observed that 14-3-3z interacted with T-bet in T C 2 cells from NDs (Fig 6, A) . Conversely, we observed a modest and comparable interaction between 14-3-3z and T-bet in T H 0 and T H 2 cells from patients with SSc and NDs. A preliminary test of 14-3-3z/ T-bet association in CD8 1 T cells compared between patients with early and late disease (defined as disease duration of <2 years or >6 years, respectively) did not reveal any significant difference (see Fig E4 in this article' s Online Repository at www.jacionline.org). 14-3-3z is only expressed in the cytosol. 29, 30 Using Western blotting, we demonstrated that levels of cytosolic 14-3-3 in CD8 1 T cells from patients and control subjects are similar (Fig 6, B) .
To establish whether the binding of 14-3-3z to T-bet affects its subcellular localization, we performed 14-3-3z siRNA silencing in CD8
1 T cells from patients with SSc and determined T-bet subcellular distribution by using Western blotting. After 14-3-3z downregulation, levels of T-bet were increased greatly in the nucleus, whereas those in the cytosol decreased (Fig 6, C) . Strikingly, we found that after 14-3-3z downregulation, the levels of IL-13 produced by CD8 1 T cells from patients with SSc decreased as well (Fig 6, D) . Moreover, we observed that IL-13 production was decreased after 14-3-3 siRNA silencing in T C 2 cells but not T H 2 cells from NDs (see Fig E5, A, in this article's Online Repository at www.jacionline.org), which diminished their ability to induce extracellular matrix production in dermal fibroblasts from patients with SSc (see Fig E5, B) .
DISCUSSION
Type 2 cytokine-producing CD8
1 T (T C 2) cells have been implicated in the pathogenesis of several inflammatory human conditions, including asthma, chronic obstructive pulmonary disease, and atopic dermatitis. [31] [32] [33] However, the molecular mechanisms underlying type 2 cytokine production by CD8 1 T cells have not been elucidated. In this report we investigated the molecular basis of IL-13 overproduction by CD8 1 T cells from patients with SSc, which is implicated in SSc-related cutaneous fibrosis. Our findings indicate that T-bet/GATA-3 nuclear interaction is diminished in CD8 1 T cells from patients with SSc compared with that in healthy control subjects, resulting in more GATA-3 becoming available to bind to the IL-13 promoter and upregulating IL-13 expression. We show that this defect depends on association of T-bet with the adaptor protein 14-3-3z in the cytosol of CD8 1 T cells from patients with SSc, restricting T-bet translocation into the nucleus (Fig 7) . Strikingly, we show that this mechanism is also found during T C 2 polarization of healthy donor CD8 1 T cells but is not observed in CD8 1 T cells from patients with RA, a chronic inflammatory condition characterized by a T H 1 and T H 17 phenotype. [34] [35] [36] [37] Thus we have identified a novel molecular mechanism in the immunopathogenesis of SSc that activates IL-13 production by CD8 1 T cells. In addition, our results indicate that this mechanism likely contributes to human T C 2 cell differentiation. CD8 1 T cells from patients with SSc express higher levels of IL-13 and GATA-3 but similar levels of IFN-g and T-bet compared with NDs. Although this finding appears to contradict the traditional paradigm of T H 1/T H 2 cell differentiation, 14, 15, [38] [39] [40] plasticity of T-cell differentiation programs has also been with SSc but not from NDs prevents in part T-bet translocation into the nucleus and its association with GATA-3. Thus more GATA-3 is available to bind to the IL-13 promoter and induce IL-13 expression.
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reported. [41] [42] [43] [44] [45] [46] [47] Type I interferons induced T H 2 cell reprogramming of lymphocytic choriomeningitis virus-infected T cells 48 and enhanced IFN-g production in CD8
1 lymphocytes. 49 Significantly, we found an interferon signature in the affected skin 50, 51 and PBMCs 52,53 of patients with SSc, which can contribute to the phenotype of CD8 1 lymphocytes from patients with SSc. An additional source of IFN-g in CD8
1 T cells from patients with SSc might come from the transcription factor Eomes, which has cooperative and redundant roles with T-bet in CD8 T-cell differentiation and function, including IFN-g production. 54, 55 Notably, we measured similar levels of Eomes expression by CD8
1 T-cell subsets from patients with SSc and NDs (data not shown), likely contributing to IFN-g expression in patients with SSc.
An unexpected result was the finding that although total levels of T-bet were comparable in CD8
1 T cells from NDs and patients with SSc, the subcellular distribution of T-bet differed. Specifically, we observed more T-bet and its active tyrosinephosphorylated form in the nuclei of CD8
1 cells from NDs compared with patients, leading to a diminished T-bet/GATA-3 interaction in the nuclei of CD8
1 lymphocytes from patients with SSc. Recently, it was shown that subcellular distribution of T-bet and Eomes identifies functional subsets of human CD8 1 T cells with increased nuclear levels in effector and effector/memory subsets and decreased levels in central memory cells. 56 In our studies we used activated total and naive CD8
1 lymphocytes, as well as freshly isolated CD8
1 cells, which are characterized in patients with SSc by higher proportions of effector and effector/ memory cells compared with control subjects 4, 5 and exhibit a strong cytolytic activity ex vivo. 5 Yet we observed lower levels of T-bet in the nuclei of patients, suggesting that T-bet subcellular localization in CD8
1 T cells from patients with SSc is likely regulated by different mechanisms.
Subcellular localization is an important mechanism controlling the effector function of many transcription factors. [56] [57] [58] [59] [60] [61] We analyzed whether T-bet tyrosine phosphorylation is involved in the transport of T-bet between the cytosol and nuclei of CD8 1 T cells. In agreement with the murine model, 16 we found that ITK is the kinase that is mainly responsible for tyrosine phosphorylation of T-bet and for its interaction with GATA-3. However, our data indicate that ITK does not affect T-bet subcellular distribution. Using mass spectrometry of T-bet-immunoprecipitated proteins from CD8
1 T cells from patients with dcSSc and control subjects, we showed that T-bet binds specifically to the adaptor protein 14-3-3z in the cytosol of patients but not in control subjects. Strikingly, we demonstrated that after silencing of 14-3-3z in CD8
1 T cells from patients with SSc, more T-bet is found in the nucleus and less IL-13 is produced, demonstrating a causal relationship between 14-3-3z and IL-13 production. Remarkably, T-bet from T C 2 cells from NDs also appears to interact with 14-3-3z but not in CD8 1 T cells purified from patients with RA. Similarly, no T-bet/14-3-3z interaction was observed in naive and freshly isolated CD4
1 T cells from patients with SSc and control subjects or in T H 2 cells from NDs, supporting our findings that this mechanism is associated with type 2 cytokine production by human T C 2 cells.
14-3-3 proteins modulate numerous cellular processes, including signal transduction, protein trafficking, cell cycling, and apoptosis, by partly affecting subcellular localization of their target proteins. 29, 30, 62, 63 Here we provide the first evidence that 14-3-3z can interact with T-bet in human CD8
1 T cells, and this interaction restricts T-bet translocation into the nucleus and promotes type 2 cytokine production. Binding of 14-3-3 depends primarily on the phosphorylation state of its target proteins. Interestingly, multiple phosphorylation forms of T-bet have been identified, which modulate lineage commitment during T-cell differentiation. 28 The predominant cytoplasmic localization of 14-3-3 proteins suggests that they might act as cytoplasmic anchors that block T-bet translocation into the nucleus. However, further studies will be necessary to elucidate the mechanisms by which 14-3-3z binding to T-bet influences its subcellular localization, as well as how these interactions are regulated.
In summary, we have identified a novel molecular mechanism underlying IL-13 overexpression by CD8
1 T cells from patients with SSc with more severe skin thickening. We also observed that CD8
1 T cells from healthy control subjects use, at least in part, the same mechanism when primed under type 2 culture conditions, thus indicating that this mechanism is likely to be applicable to the development of T C 2 cells in other human inflammatory conditions. This more complete picture of the complex pathway leading to disease pathogenesis will aid in the development of novel markers of immune dysfunction and potential therapeutic targets.
FIG E1. T-bet/GATA-3 association in CD8
1 T cells from patients with RA.
Expression of T-bet determined by means of immunoblotting in CD8 1 T cells from patients with RA (n 5 6) and NDs (n 5 6). Actin was used as a loading control. Cell lysates were immunoprecipitated with anti-T-bet or IgG control antibodies and then immunoblotted with anti-GATA-3, anti-14-3-3, or anti-T-bet antibodies. Representative examples are shown. Forty micrograms of proteins from total cell lysates were subjected to SDS-PAGE for Western blotting. 22 The following mAbs were used for Western blotting: anti-GATA-3 (Abcam), anti-T-bet (Santa Cruz Biotechnology), anti-14-3-3 (Cell Signaling), and anti-actin (Sigma-Aldrich). For immunoprecipitation, we used anti-T-bet mAb (Santa Cruz Biotechnology). Immunoprecipitation of protein lysates was performed with the Protein G immunoprecipitation kit (Sigma-Aldrich), according to the manufacturer's protocol. In control samples the primary antibody was substituted with nonimmune IgG. Samples were obtained from patients with RA enrolled in the Rheumatoid Arthritis Comparative Effectiveness Research (RACER) registry at the University of Pittsburgh after obtaining written informed consent. Data collected in RACER include age, sex, race/ethnicity, disease duration, disease activity assessed by using the Clinical Disease Activity Index (CADI) and DAS28-CRP (C-reactive protein) scores, current medications, treatment change, and laboratory tests, including rheumatoid factor, and CCP2 antibodies are also measured at each RACER visit. Patients recruited included subjects with active RA receiving disease-modifying anti-rheumatic drug/ anti-TNF therapy. All RACER studies received Institutional Review Board approval at the University of Pittsburgh, and this study was carried out in accordance with the approved guidelines. IP, Immunoprecipitation; WB, Western blotting.
FIG E2.
Cytokine production by T-cell subsets from healthy control subjects and patients with SSc. Intracellular cytokine staining was used to determine the proportion of IL-13
1 and IFN-g 1 cells by in vitroactivated naive CD4 1 and CD8 1 T cells from NDs primed under type 1 or type 2 culture conditions. Briefly, cells were cultured for 5 days (T H 0 or T C 0) in complete RPMI 1640 medium and activated with beads coated with anti-CD3 and anti-CD28 antibodies (Dynabeads CD3/CD28 T cell Expander; bead-to-cell ratio, 1:1; Dynal Biotech-Invitrogen) and rhIL-2 (20 U/mL; PeproTech, Rocky Hills, NJ). T H 1 and T C 1 differentiation was facilitated by addition of hIL-12 (2 ng/mL; PeproTech) and anti-IL-4 mAb (50 mg/mL; R&D Systems, Minneapolis, Minn) to the cell culture. T H 2 and T C 2 differentiation was achieved by adding rhIL-4 (100 U/mL; PeproTech) and anti-IFN-g mAb (50 mg/mL; R&D Systems). 7 A, A representative example is shown. B, Comparison of the mean percentage of cytokine-positive cells in each T-cell subset. Each symbol represents 1 patient or a control subject. Statistics were determined by means of ANOVA, followed by the post hoc Tukey test. Intracellular cytokine staining was performed, as previously described. 4 C, Cytokine production by CD8 1 and CD4
1
T cells isolated from the peripheral blood of NDs (CD8, n 5 23; CD4, n 5 10) or patients with SSc (CD8, n 5 43; CD4, n 5 20). Statistics were determined by using the Student t test. D, Comparison of cytokine production by CD4 1 and CD8 1 T cells isolated from the affected skin of patients with early active dcSSc (n 5 5).
Statistics were determined by using ANOVA, followed by the Tukey post hoc test. **P < . 01 and ***P < .001.
FIG E3.
Identification of T-bet-interacting proteins using immunoprecipitation and mass spectrometry. CD8 1 T cells from 2 patients with early dcSSc and 2 NDs were activated in vitro for 5 days and immunoprecipitated with anti-T-bet or control IgG antibodies, as described above. Immunoprecipitated proteins were separated by using SDS-PAGE gel electrophoresis and stained with Coomassie Brilliant Blue. Several bands were excised from the gel and trypsin digested, and the resulting peptide fragments were sequenced by means of mass spectrometry. A, A gel band of approximately 30 kDa was detected in both patient samples but not in control samples. B, Liquid chromatography-tandem mass spectrometry was performed at the Biomedical Mass Spectrometry Center at the University of Pittsburgh. Bottom-up proteomics experiments were conducted with a Thermo-Finnegan Velos-Orbitrap (Velos Orbi) mass spectrometer coupled to a Waters nanoAcquity ultra-high-pressure liquid chromatography system through a nanoelectrospray ionization source. Mascot or X!Tandem search engines with a decoy search at a 1% false discovery rate was used to identify proteins present in the excised ban, which was identified as 14-3-3 zeta (14-3-3z). A representative tandem mass spectrometry spectrum is presented in Fig E3, B . 
FIG E5.
Effect of 14-3-3 silencing on T H 2 and T C 2 cells from healthy control subjects. A, CD4 1 and CD8 1 T cells were isolated from the peripheral blood of 5 healthy donors. Cells were nucleofected with 14-3-3 or control siRNAs and primed under type 2 polarizing conditions (T H 2 and T C 2). IL-13 production was determined by means of intracellular staining, followed by flow cytometry. Experimental procedures for cell isolation, siRNA silencing, cell culture, and cytokine staining were performed, as reported in the Methods section. A representative example of 5 procedures performed is shown. B, Dermal fibroblasts isolated from skin biopsy specimens from 2 patients with early active dcSSc were cultured for 24 hours with supernatants from T H 2 or T C 2 cells from NDs with or without 14-3-3z silencing by siRNA, as described in Fig E5, A. Collagen (COL1A1) production was determined in culture media by using Western blotting, as previously described. 4, 5 A representative experiment of 5 independent experiments producing similar results is shown. The intensity of staining is expressed in arbitrary units: -, no staining; 1, positive (<30% cells); 11, positive staining (30% to 60% cells); 111, positive (>60% cells).
